Published: 2023 April 04

Preeclampsia Diagnostics Market Trends, Share, Size, Growth, Insights and Market Forecast 2023-2030

SKU : MD2588
180 pages
Report Summary
Table of Contents
List of Tables & Figures

Preeclampsia Diagnostics Market is segmented By Product Type (Instruments, Consumables), By Test Type (Blood Tests, Urine Analysis), By End-User (Hospitals, Diagnostic Centers, Specialty Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030


Preeclampsia Diagnostics Market Overview

Preeclampsia Diagnostics Market size was valued US$ 1.03 billion in 2021 and is estimated to reach US$ 1.24 billion by 2029, growing at a CAGR of 11.0% during the forecast period (2023-2030). Preeclampsia is a major cause of illness and deaths among mothers and their babies globally. It is characterized by elevated blood pressure and excessive protein in the urine of pregnant women which can cause the baby delivered preterm and smaller than usual. This severe pregnancy disorder occurs in up to 5% of all pregnancies. It is one of the leading hypertensive disorders of pregnancy across the developed and emerging countries. If it is not diagnosed at an early stage, then it may lead to preterm birth and other complications, such as failure of organs, seizure or eclampsia, and death. For instance, according to the Preeclampsia Foundation, it has been estimated that pregnancy-induced hypertension is responsible for causing 76,000 maternal and 500,000 infant deaths each year globally.

As per DataM Intelligence, Preeclampsia Diagnostics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Preeclampsia Diagnostics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Preeclampsia Diagnostics Market in the United States and Canada produces the utmost share. Whereas the European Preeclampsia Diagnostics Market is projected to continue its presence globally during the period of 2023-2030.


Preeclampsia Diagnostics Market Summary and Scope





Segments Covered

By Product Type, By Test Type, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Regions Analyzed

North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.

Major Companies Covered

Abbott Laboratories, EKF Diagnostics Holdings plc, BioMérieux SA, Atlas Medical, Quidel Corporation, BIOSYNEX SA, Prestige Brands Holdings, Swiss Precision Diagnostics (SPD) GmbH, Piramal Enterprises, NG BIOTECH SAS, and among the major companies listed in the final report.


To know more insights into the Diagnostic Imaging Market, get our Sample Brochure


Preeclampsia Diagnostics Market Dynamics and Trends

The rising incidences of preeclampsia globally. The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market.

Rapidly growing demand for its diagnosis and treatments are expected to drive market growth.

The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market. According to the Preeclampsia Foundation, more than 10 million women globally develop preeclampsia every year, and around 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in developed and developing nations. According to the World Health Organization (WHO), the prevalence of preeclampsia is seven times higher in emerging countries as compared to developed countries. Also, as per a report by BioMed Central (BMC), the incidence of preeclampsia ranges from 1.8% to 16.7% in developing economies. It affects around 10% of pregnant women in the African continent. The rise in maternal & perinatal mortality and morbidity rates is projected to increase the demand for early diagnosis of preeclampsia among pregnant women.

In addition, increasing research and development to innovative new tests to detect biomarkers indicating preeclampsia is expected to boost the market growth over the forecast period. For instance, in November 2022, a team of researchers at the RCSI Department of Obstetrics and Gynaecology at the Rotunda Hospital, Dublin launched three research studies that examined the experiences and impact of diabetes in women, ahead of World Diabetes Day 2022. The three studies have been awarded total funding of €1.1 million in this region by the Health Research Board (HRB) and the European Commission. The IRELAnD Trial will examine the role that aspirin improves the health of pregnant women with diabetes. This is the first study to examine the impact of low-dose aspirin for the prevention of preeclampsia (high blood pressure during pregnancy) in women with diabetes.

Also in July 2020, researchers from the University of Helsinki have shown that HLA-G gene regulates the male-to-female ratio at birth. The study strengthens earlier findings of the vulnerability of male fetuses to preeclampsia.

Lack of awareness about Preeclampsia in developing countries is expected to hamper the market growth.

The lack of awareness about the effective screening tools for the condition among the healthcare providers and increasing knowledge about the signs & symptoms associated with preeclampsia among pregnant mothers and are likely to boost the preeclampsia diagnostics market growth rapidly over the forecast period.

Industry Analysis

The global preeclampsia diagnostics Market provides in-depth analysis of the market based on various industry factors such as Porter’s Five Forces, Regulatory & Reimbursement Analysis, Value Chain Analysis, Pricing Analysis, Technological Advancements, Epidemiology etc.

Preeclampsia Diagnostics Market Segmentation Analysis

Blood tests segment is expected to hold the largest market share in global preeclampsia diagnostics market

The blood tests accounted for the largest market share of the preeclampsia diagnostics market in 2022, owing to the several advantages of blood tests in detecting the biomarkers efficiently which are responsible for preeclampsia. Several organizations are highly adopting blood tests as a better test for the detection of preeclampsia. With advancements in technology, new tests are being introduced in the market, which are further boosting the blood test market growth. For instance, the NHS England approved two blood test products named Elecsys sFlt-1 and PlGF immunoassays of F. Hoffmann-La Roche under the ‘Innovation and Technology Payment’ program in June 2022. The NHS aims to implement the usage of innovative products within the hospitals in Europe and enhance the accessibility of diagnostic tools for preeclampsia among healthcare professionals to detect pregnancy-induced hypertension.

Preeclampsia Diagnostics Market Geographical Share

North America region holds the largest market share in the global preeclampsia diagnostics market

North America region is dominating the global preeclampsia diagnostics market accounting for the largest market share in 2022, owing to the increasing healthcare expenditure, adoption of highly advanced products, growing awareness towards preeclampsia among the patients and healthcare providers regarding the severity of the condition. The increasing prevalence of preeclampsia is leading to an increase in medical treatment cost among women with preeclampsia and their newborns. For instance, according to the American Journal of Obstetrics and Gynecology (AJOG), the total cost of maternal healthcare with preeclampsia was around one-third of the total U.S. healthcare costs of women with preeclampsia.

Preeclampsia Diagnostics Companies and Competitive Landscape

The Preeclampsia Diagnostics market is dominated by major players including Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG Instruments GMBH, Metabolomic Diagnostics Ltd., Bayer AG, Sera Prognostics, among others.

Global Preeclampsia Diagnostics Market – Key Companies to Watch

F. Hoffmann-La Roche Ltd

Overview: Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is one of the largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche is global leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management.

Product Portfolio: Elecsys sFlt-1/PlGF- immunoassays for preeclampsia are the first available and approved automated diagnostic tests for fast and easy assessment in a clinical conext.

The global preeclampsia diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.


Trending Topics

Tissue Diagnostics Market

Vehicle Diagnostics Market

Food Diagnostics Market 

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
What is the Projected CAGR value of the Preeclampsia Diagnostics Market?
Preeclampsia Diagnostics Market is expected to grow at a CAGR of 11% during the forecasting period 2023-2030.
Which is the fastest growing region in the Preeclampsia Diagnostics Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period